



Neurocrine Biosciences Announces NBI-98854 Scientific Presentations at the International Parkinson and Movement Disorder Society's 18th Annual Congress

February 25, 2014

DATA FROM KINECT 1 AND KINECT 2 STUDIES WILL BE PRESENTED

SAN DIEGO, Feb. 25, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that two NBI-98854 scientific abstracts have been accepted for the scientific program at the 2014 Annual Congress of Parkinson's Disease and Movement Disorders, to be held June 8-12, 2014 in Stockholm Sweden. This annual meeting draws over 5,000 experts from around the world to address current topics related to movement disorders.

"We are very pleased to participate in the Annual Congress of Parkinson's Disease and Movement Disorders," said Chris O'Brien, M.D., Chief Medical Officer at Neurocrine. "This is the most important meeting for movement disorders that brings together clinicians and scientists from around the globe. Having abstracts for both Kinect 1 and Kinect 2 accepted for presentation at this prestigious meeting allows us to share the breadth of our tardive dyskinesia clinical efforts during the congress."

An abstract from the Kinect 1 study of NBI-98854 for the treatment of tardive dyskinesia entitled "Kinect 1 Extension: 12-week treatment of Tardive Dyskinesia with NBI-98854" and an abstract of the Kinect 2 study of NBI-98854 entitled "Kinect 2: NBI-98854 Treatment of Moderate to Severe Tardive Dyskinesia" are scheduled to be presented by the Company on June 11, 2014 in Stockholm. Both of these abstracts will describe the methodology of each clinical trial, safety and efficacy results, and statistical findings along with key clinical observations.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers and develops innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel R&D platform, focused on neurological and endocrine based diseases and disorders. The Company's two lead late-stage clinical programs are elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc., and a wholly owned vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders. Neurocrine intends to maintain certain commercial rights to its VMAT2 inhibitor for evolution into a fully-integrated pharmaceutical company.

Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at <http://www.neurocrine.com>.

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, and Company overall. In addition, the Company faces risks and uncertainties with respect to the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2013. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

SOURCE Neurocrine Biosciences, Inc.

Investor Relations, +1-858-617-7600